ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Yunpi Qufeng Chushi Formula for Pre-Rheumatoid Arthritis: Study Protocol for a Multiple-Center, Double-Blind, Placebo-Controlled Randomized Controlled Trial

Tang, Yujun; Li, Haichang; Huang, Lin; Wang, Qiao; Han, Yongmei; Wu, Huaxiang; Su, Xiao; Hou, Xiujuan; Huang, Chuanbing; Lin, Changsong; Tao, Qingwen; Tang, Jinyang; Cao, Wei*; Xie, Zhijun*; Wen, Chengping*广州中医药大学; 浙江大学; 1
Frontiers in Pharmacology2022-2-14DOI: 10.3389/fphar.2022.793394
1被引13阅读
引用收藏
分享

摘要

Introduction: Rheumatoid arthritis (RA) is an autoimmune disease characterized by progressive bone erosion on diarthrodial joints. RA patients usually experienced three stages before final diagnosis: the health period, the pre-clinical period (immune response exists without clinical symptoms), and the pre-RA period (immune response exists with mild inflammatory manifestation). Presently, there is seldom guidance referring to early intervention which is a benefit for stable disease conditions and low morbidity. Prophylactic treatment is a major feature of traditional Chinese medicine (TCM). In this present study, a multi-center, double-blind, placebo-controlled clinical trial is carried out to evaluate both efficacy and safety in preventing RA progression on Yunpi Qufeng Chushi formula (YQCF). @@@ Method: The multi-center, double-blind, placebo-controlled clinical trial is conducted in 13 hospitals nationwide. A total of 390 patients ages between 18 and 70 will be recruited in the trial. They will be randomly assigned to the intervention group (YQCF) and placebo group. The follow-up visit will be taken every 3 months from baseline to 1 year. Diagnosis, disease activity scores, clinical disease activity index (CDAI), simplified disease activity index (SDAI), TCM syndrome scores, and safety assessments will be recorded at every visit. Joint color doppler ultrasound, health assessment questionnaire-disability index (HAQ-DI), and functional assessment of chronic illness therapy-fatigue (FACIT-F) will be recorded at baseline and the last visit. @@@ Discussion: This work will provide evidence of YQCF in preventing RA progression. However, whether early intervention would benefit the controlling RA disease still needs a long-term follow-up. @@@ Ethics and dissemination: Protocol version 2 (201910-1). This research was approved by the medical ethics committee of Zhejiang Chinese Medical University (2019-045). Results will be published in a peer-reviewed academic journal.

学科与关键词

关键词
pre-rheumatoid arthritisrandomized controlled trialdouble-blindChinese medicineplaceboprotocol
相关
加载中…
  • Real-world effects of Yishen Tongbi decoction for rheumatoid arthritis: protocol for a prospective, observational, multicenter cohort study with validation against double-blind, randomized, controlled trial
    Liu, Lijuan; Zhu, Fangfang; Xin, Yijun; Zhang, Lu; Hu, Congqi; Xu, Yanping; Zhang, Jinming; Liu, Lingjie; Chen, Guangxing*Frontiers in Pharmacology, 2024, 15: 1320578.
  • Where traditional Chinese medicine meets Western medicine in the prevention of rheumatoid arthritis
    Jakobsson, Per-Johan*; Robertson, Luke; Welzel, Janika; Zhang, Mingshu; Yang Zhihua; Gao Kaixin; Huang Runyue; Wen Zehuai; Korotkova, Marina; Goransson, UlfJournal of Internal Medicine, 2022, 292(5): 745-763.被引 13
  • Effectiveness of Yishen Tongbi decoction versus methotrexate in patients with active rheumatoid arthritis: A double-blind, randomized, controlled, non-inferiority trial
    Xu, Jia; Zhang, Lu; Xu, Yanping; Yu, Jiahui; Zhao, Lianyu; Deng, Hui; Li, Meiling; Zhang, Mingying; Lei, Xujie; Hu, Congqi; Jiao, Wei; Dai, Zhao; Liu, Lijuan*; Chen, Guangxing*PHYTOMEDICINE, 2023, 112: 154704.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-02-14
卷期
第 13 卷
页码
793394
DOI
10.3389/fphar.2022.793394
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Key R&D Program of China [2018YFC1705500]; Zhejiang Nature Science Foundation [LQ20H270006]

作者

  • T

    Tang, Yujun (第一作者)

    zhejiang chinese med univ

  • L

    Li, Haichang

    zhejiang chinese med univ

查看全部 15 位作者收起作者
  • H

    Huang, Lin

    zhejiang chinese med univ

  • W

    Wang, Qiao

    zhejiang chinese med univ

  • H

    Han, Yongmei

    zhejiang univ

  • W

    Wu, Huaxiang

    2 · zhejiang univ

  • S

    Su, Xiao

    shanghai municipal hosp tradit chinese med · shanghai univ tradit chinese med

  • H

    Hou, Xiujuan

    beijing univ chinese med

  • H

    Huang, Chuanbing

    1 · anhui univ

  • L

    Lin, Changsong

    1 · guangzhou univ chinese med

  • T

    Tao, Qingwen

    china japan friendship hosp

  • T

    Tang, Jinyang

    xiyuan hosp

  • C

    Cao, Wei (通讯)

    wangjing hosp

  • X

    Xie, Zhijun (通讯)

    zhejiang chinese med univ

  • W

    Wen, Chengping (通讯)

    zhejiang chinese med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417